Urofacial syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2704OMIM:236730N31.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Urofacial syndrome (UFS), also known as Ochoa syndrome, is a rare autosomal recessive disorder characterized by the combination of a severe lower urinary tract dysfunction and an abnormal facial expression. The condition was first described by Colombian physician Bernardo Ochoa in 1987. The hallmark facial feature is an inverted or grimacing expression when attempting to smile or laugh — the face appears as though the individual is crying or in distress when they are actually expressing happiness. This distinctive facial expression is caused by abnormal co-contraction of facial muscles. The urinary tract dysfunction in urofacial syndrome involves detrusor-sphincter dyssynergia, where the bladder muscle and the urethral sphincter contract simultaneously rather than in a coordinated fashion. This leads to incomplete bladder emptying, urinary incontinence, recurrent urinary tract infections, vesicoureteral reflux, and hydronephrosis. If left untreated, the progressive urinary obstruction can result in severe kidney damage and end-stage renal failure, which is the most serious complication of the condition. Constipation and fecal soiling may also occur due to similar dyscoordination affecting bowel function. Urofacial syndrome is caused by pathogenic variants in the HPSE2 gene (UFS1, on chromosome 10q24) or the LRIG2 gene (UFS2, on chromosome 1p13). These genes are involved in neural development and signaling pathways important for proper innervation of the bladder and facial muscles. Treatment is primarily supportive and focuses on preserving kidney function. Management includes clean intermittent catheterization to ensure complete bladder emptying, prophylactic antibiotics to prevent urinary tract infections, anticholinergic medications to reduce bladder overactivity, and in some cases surgical interventions such as vesicostomy or bladder augmentation. Early diagnosis and aggressive urological management are critical to preventing irreversible renal damage.

Also known as:

Clinical phenotype terms— hover any for plain English:

Urethral obstructionHP:0000796
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Urofacial syndrome.

View clinical trials →

No actively recruiting trials found for Urofacial syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Urofacial syndrome community →

No specialists are currently listed for Urofacial syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Urofacial syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Urofacial syndromeForum →

No community posts yet. Be the first to share your experience with Urofacial syndrome.

Start the conversation →

Latest news about Urofacial syndrome

No recent news articles for Urofacial syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Urofacial syndrome

What is Urofacial syndrome?

Urofacial syndrome (UFS), also known as Ochoa syndrome, is a rare autosomal recessive disorder characterized by the combination of a severe lower urinary tract dysfunction and an abnormal facial expression. The condition was first described by Colombian physician Bernardo Ochoa in 1987. The hallmark facial feature is an inverted or grimacing expression when attempting to smile or laugh — the face appears as though the individual is crying or in distress when they are actually expressing happiness. This distinctive facial expression is caused by abnormal co-contraction of facial muscles. The u

How is Urofacial syndrome inherited?

Urofacial syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Urofacial syndrome typically begin?

Typical onset of Urofacial syndrome is childhood. Age of onset can vary across affected individuals.